Features of the development of cognitive impairment in patients with type 2 diabetes mellitus and metabolic syndrome

DOI: https://doi.org/10.29296/25877305-2018-09-01
Download full text PDF
Issue: 
9
Year: 
2018

V. Shishkova(1), Candidate of Medical Sciences; L. Kapustina(2), Candidate of Medical Sciences 1-Center for Speech Pathology and Neurorehabilitation, Moscow 2-City Polyclinic Sixty-Nine, Moscow Healthcare Department

Type 2 diabetes mellitus (DM) is one of the most important independent risk factors for cognitive impairment (CN) and dementia. The presence of possible CN or its development in a patient with DM should be taken into account when choosing the right combination therapy. Each patient with DM should be treated individually, by taking into consideration the clinical features and possible complications, as well as the presence of comorbid vascular diseases. When choosing cognitive function-improving drugs, it is necessary to keep in mind their other positive as well as direct effects, their tolerability and the possibility of their safe combination in combination therapy.

Keywords: 
neurology
endocrinology
type 2 diabetes mellitus
metabolic syndrome
chronic cerebral ischemia
cognitive impairment



It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

References: 
  1. DeFronzo R., Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease // Diabetes Care. – 1991; 14 (3): 173–94.
  2. Dedov I.I., Shestakova M.V. Saharnyj diabet / M.: Meditsinskoe Informatsionnoe Agentstvo, 2005; 677 s.
  3. Rosenzweig J., Ferrannini E., Grundy S. et al. Primary prevention of cardiovascular disease and type 2 diabetes in patients at metabolic risk: an Endocrine Society clinical practice guideline // J. Clin. Endocrinol. Metab. – 2008 93 (10): 3671–89.
  4. Brands J. et al. Obesity and Hypertension: Roles of Hyperinsulinemia, Sympathetic Nervous System and Intrarenal Mechanisms // J. Nutr. – 1995; 125 (6): 1725–31.
  5. Nigro J., Osman N., Dart A. et al. Insulin resistance and atherosclerosis // Endocrine Rev. – 2006; 27 (3): 242–59.
  6. Stamler J., Vaccaro O., Neaton J. et al. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial // Diabetes Care. – 1993; 16: 434–44.
  7. Stegmayr B., Asplund K. Diabetes as a risk factor for stroke. A population perspective // Diabetologia. – 1995; 38: 1061–8.
  8. Stewart R., Liolitsa D. Type 2 diabetes mellitus, cognitive impairment and dementia // Diabetic Med. – 1999; 16 (2): 93–112.
  9. Zaharov V.V., Sosina V.B. Kognitivnye narushenija u bol'nyh saharnym diabetom // Nevrol. zhurn. – 2009; 4 (14): 54–8.
  10. Kalinin A.P., Kotov S.V. Nevrologicheskie rasstrojstva pri endokrinnyh zabolevanijah / M.: Meditsina, 2001; 272 s.
  11. Shishkova V.N. Vzaimosvjaz' razvitija metabolicheskih i kognitivnyh narushenij u patsientov s saharnym diabetom, prediabetom i metabolicheskim sindromom // Consilium Medicum (Nevrologija/revmatologija). – 2010; 1: 36–43.
  12. Vanhanen M., Koivisto K., Karjalainen L. et al. Risk for non-insulin-dependent diabetes in the normoglycaemic elderly is associated with impaired cognitive function // Neuroreport. – 1997; 8 (6): 1527–30.
  13. Kalmijn S., Feskens E., Launer L. et al. Glucose intolerance, hyperinsulinaemia and cognitive function in a general population of elderly men // Diabetologia. – 1995; 38 (9): 1096–102.
  14. Balabolkin M.I., Kreminskaja V.M., Klebanova E.M. Rol' okislitel'nogo stressa v patogeneze diabeticheskoj nejropatii i vozmozhnost' ego korrektsii preparatami α-lipoevoj kisloty // Problemy endokrinol. – 2005; 51 (3): 22–32.
  15. Pasquier F. et al. Diabetes mellitus and dementia // Diabetes Metab. – 2006; 32 (5 Pt 1): 403–14.
  16. Ott A., Stolk R., van Harskamp F. et al. Diabetes mellitus and the risk of dementia: The Rotterdam Study // Neurology. – 1999; 53 (9): 1937–42.
  17. Bondareva V.M., Chistjakova O.V. Insulin i insulinretseptornaja signal'naja sistema mozga // Nejrohimija. Akademizdat-tsentr «Nauka» RAN. – 2007; 24: 8–20.
  18. Gasparini L. et al. Does insulin dysfunction play a role in Alzheimers disease? // Trends Pharmacol. Sci. – 2002; 23 (6): 288–393.
  19. Areosa S., Grimley E. Effect of treatment of type II diabetes mellitus on the development of cognitive impairment and demencia // Cochrain Database Syst. Rev. – 2002; 4: CD003804.
  20. Shishkova V.N. Kognitivnye narushenija kak universal'nyj klinicheskij sindrom v praktike terapevta // Ter. arh. – 2014; 11: 128–34.
  21. Shishkova V.N. Osobennosti razvitija nevrologicheskih oslozhnenij u patsientov s metabolicheskim sindromom: vozmozhnost' korrektsii i profilaktiki // Ter. arh. – 2015; 1: 109–14.
  22. Albretch E. et al. The effects of Cereblysin on survival and sprouting of neurons from cerebral hemispheres and from the brainstem of chick embryons in vitro // Adv. Biosci. – 1993; 87: 341–2.
  23. Gomazkov O.A. Nejrotroficheskie i rostovye faktory mozga: reguljatornaja spetsifika i terapevticheskij potentsial // Uspehi fiziol. nauk. – 2005; 36 (2): 1–25.
  24. Gromova O.A., Torshin I.Ju., Gogoleva I.V. Mehanizmy nejrotroficheskogo i nejroprotektornogo dejstvija preparata tserebrolizin pri ishemii golovnogo mozga // Zhurn. nevrol. i psihiat. im. S.S. Korsakova. – 2014; 3 (2): 43–50.
  25. Chen H. et al. Trophic factors counteract elevated FGF-2-induced inhibition of adult neurogenesis // Neurobiol. Aging. – 2007; 28 (8): 1148–62.
  26. Boado J. Brain-derived peptides regulate the steady state levels and increase stability of the blood-brain barrier GLUT1 glucose transporter mRNA // Neurosci. Letters. – 1995; 197: 179–82.
  27. Boado J. Blood-brain barrier GLUT1 glucose transporter molecular level regulation by brain-derived peptides // J. Neural. Transm. – 1998; 53: 323–31.
  28. Stewart P., Wiley M. Developing nervous tissue induces formation of blood-brain characteristics in invading endothelial cells: a study using quail-chick transplantation chimera // Dev. Biol. – 1981; 84: 183–92.
  29. Pawlikowska L. et al. Association of common genetic variation in the insulin/IGF1 signaling pathway with human longevity // Aging Cell. – 2009; 8 (4): 460–72. DOI: 10.1111/j.1474-9726.2009.00493.x.
  30. Chunling Zhang, Michael Chopp et al. Cerebrolysin Enhances Neurogenesis in the Ischemic Brain and Improves Functional Outcome After Stroke // J. Neurosci. Res. – 2010; 88: 3275–81.
  31. Ubhi K., Rockenstein E., Vazquez-Roque R. et al. Cerebrolysin Modulates Pronerve Growth Factor/Nerve Growth Factor Ratio and Ameliorates the Cholinergic Deficit in a Transgenic Model of Alzheimer’s Disease // J. Neurosci. Res. – 2013; 91: 167–77.
  32. Rockenstein E. et al. Cerebrolysin Decreases Amyloid-β Production by Regulating Amyloid Protein Percursor Maturation in a Transgenic Model of Alzheimer’s Disease // J. Neurosci. Res. – 2006; 83: 1252–61.
  33. Ubhi K. et al. Neurofi brillary and neurodegenerative pathology in APP-transgenic mice injected with AAV2-mutant TAU: neuroprotective effects in Cerebrolysin // Acta Neuropathol. – 2009; 117: 699–712.
  34. Masliah E., Diez-Tejedor E. The pharmacology of neurotrophic treatment with Cerebrolysin: brain protection and repair to counteract pathologies of acute and chronic neurological disorders // Drugs Today (Barc). – 2012; 48 (Suppl. A): 3–24. DOI: 10.1358/dot.2012.48(Suppl.A).1739716.
  35. Shishkova V.N., Zotova L.I., Maljukova N.G. i dr. Otsenka vlijanija terapii tserebrolizinom u patsientov s postinsul'tnoj afaziej na uroven' BDNF v zavisimosti ot nalichija ili otsutstvija narushenij uglevodnogo obmena // Zhurn. nevrol. i psihiat. im. S.S. Korsakova. – 2015; 5: 57–63.
  36. Shishkova V.N., Zotova L.I., Remennik A.Ju. i dr. Vlijanie Tserebrolizina na postinsul'tnuju afaziju i uroven' faktora rosta nervov pri narushenijah uglevodnogo obmena // Doktor.ru (Nevrologija/psihiatrija). – 2015; 5 (106): 25–30.
  37. Shishkova V.N., Zotova L.I., Remennik A.Ju. i dr. Dinamika urovnja tsiliarnogo nejrotroficheskogo faktora u patsientov s postinsul'tnoj afaziej i narushenijami uglevodnogo obmena na fone terapii // Obozrenie psihiat. i med. psihol. im. V.M. Behtereva. – 2015; 4: 129–37.
  38. Chen N., Yang M., Guo J. et al. Cerebrolysin for vascular dementia // Cochrane Database Syst. Rev. – 2013; 1: CD008900.
  39. Gauthier S. et al. Cerebrolysin in Mild-to – Moderate Alzheimer’s Disease: A Meta-Analysis of Randomized Controlled Clinical Trials // Dement. Geriatr. Cogn. Disord. – 2015; 39: 340–55.